AI assistant
Sending…
Wave Life Sciences Ltd. — Director's Dealing 2022
Oct 29, 2022
31900_dirs_2022-10-28_35bf6db4-babb-4deb-8fe9-446d5a238c77.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Wave Life Sciences Ltd. (WVE)
CIK: 0001631574
Period of Report: 2022-10-27
Reporting Person: Verdine Gregory L. (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-10-27 | Share Option (right to buy) | $4.37 | A | 163467 | Acquired | 2027-10-27 | Ordinary Shares (163467) | Direct |
Footnotes
F1: The reporting person was granted this option pursuant to his existing consulting agreement with Wave. The option vests in equal monthly installments beginning on October 31, 2022, through December 31, 2024, subject to the reporting person's continued services through the applicable vesting date.
More from Wave Life Sciences Ltd.
Regulatory Filings
2026
May 18
Interim / Quarterly Report
2026
Apr 28
Regulatory Filings
2026
Apr 28
Regulatory Filings
2026
Apr 21
Regulatory Filings
2026
Apr 15
Major Shareholding Notification
2026
Mar 31
Director's Dealing
2026
Mar 31
Regulatory Filings
2026
Mar 26
Director's Dealing
2026
Feb 28
Annual Report
2026
Feb 26